News Hub | News Direct

SC Johnson and Global Fund Launch Partnership to Eradicate Malaria; Urge World Leaders to Boost Action to End One of the World’s Deadliest Diseases

SC Johnson

SC Johnson has teamed up with the Global Fund to accelerate the elimination of malaria, a deadly yet preventable and treatable disease that claims the life of a child under the age of five every minute. In addition to announcing their partnership, the two organizations are calling on leaders attending the 2022 Commonwealth Heads of Government Meeting (CHOGM) in Kigali to redouble their efforts to help eliminate the disease. Under an agreement signed by Peter Sands, Executive Director of the Global Fund, and Fisk Johnson, Chairman and CEO of SC Johnson, the partnership will leverage SC Johnson’s core competencies in entomology to drive measurable and economically sustainable social impact in the malaria space in Burundi, Democratic Republic of Congo, Kenya, Rwanda, South Sudan, Tanzania, Uganda and Zanzibar. “Malaria claims the lives of hundreds of thousands of children every year, and yet it remains one of the most neglected diseases on the planet,” said Fisk. “We’ve been working for decades on preventative interventions and innovative solutions, such as spatial repellents, to help those most at risk. We know we can’t tackle this insidious disease alone. That’s why we are partnering with the Global Fund and calling on leaders here in Kigali to redouble their efforts to help end malaria once and for all.” For more than 60 years, SC Johnson has studied insects and the diseases they carry at the company’s Center for Insect Science and Family Health, one of the world’s largest privately funded urban entomology centers. SC Johnson has leveraged that knowledge and expertise to help protect families from insect-borne diseases like malaria and dengue. As part of this partnership, SC Johnson will be providing technical knowledge to support country-led efforts to eliminate malaria. “SC Johnson’s strong expertise in entomology can be a key asset in supporting our partners to accelerate progress in the fight against malaria,” said Peter. “This new initiative is a great example of how the private sector can bring innovative solutions and technical expertise to bear on the fight against the world’s deadliest diseases. Ahead of the Global Fund’s Seventh Replenishment, we will continue to count on our private sector partners to invest with us to defeat HIV, TB and malaria, end health inequity and protect humanity from pandemics.” The Global Fund provides 56% of all international financing for malaria programs (39% of total available resources) and has invested more than US$16 billion in malaria control programs to date. In countries where the Global Fund invests, malaria deaths have dropped by 26% between 2002 and 2020. The announcement comes ahead of the Global Fund’s Seventh Replenishment Conference hosted by U.S. President Joe Biden later this year. The Global Fund’s target is to raise at least US$18 billion to fund its next three-year cycle of grants. A successful Replenishment would save 20 million lives, cut the death rate from HIV, tuberculosis and malaria by 64%, and strengthen systems for health to build a healthier, more equitable world. In the fight against malaria, a successful Replenishment would cut malaria deaths by 62%, reduce malaria cases by 66% and eliminate malaria from an additional six countries by 2026. About the Global Fund The Global Fund is a worldwide movement to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. We raise and invest more than US$4 billion a year to fight the deadliest infectious diseases, challenge the injustice which fuels them and strengthen health systems in more than 100 of the hardest hit countries. Since the beginning of the COVID-19 pandemic, we have invested an additional US$4.3 billion to fight the new pandemic and reinforce systems for health. We unite world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. Since 2002, the Global Fund has saved 44 million lives. Information on the work of the Global Fund is available at www.theglobalfund.org Follow the Global Fund on Twitter: http://twitter.com/globalfund Join the Global Fund on Facebook: http://www.facebook.com/theglobalfund About SC Johnson Founded in 1886 and headquartered in Racine, Wisconsin USA, SC Johnson believes that a more sustainable, healthier and transparent world that inspires people and creates opportunities isn't just possible – it’s our responsibility. A heritage of innovation and bold, transparent decisions is why our high-quality products and iconic brands – including OFF! ®, Raid ®, Glade ®, Windex ®, Scrubbing Bubbles ®, Ziploc ®, Mrs. Meyer’s Clean Day ®, method ®, Autan ®, Baygon ®, Mr Muscle ®, Duck ®, Lysoform ® and more – are in homes, schools and businesses in virtually every country worldwide. As a global, purpose-led company, we are committed to making the world a better place today and for future generations. That means relentlessly bringing our expertise in science, innovation and partnerships to bear on some of the world's most pressing environmental and health issues like reducing plastic waste and eradicating malaria. Around the world, we use our resources to unlock greater economic and educational opportunities for people and communities where access may be limited, but curiosity and potential are limitless. See how SC Johnson is a Family Company At Work For a Better World by visiting scjohnson.com or joining us on Facebook, Twitter, LinkedIn, Instagram and YouTube. Contact Details SC Johnson Jen Erickson +1 262-598-6726 jericks@scj.com Company Website https://www.scjohnson.com/

June 22, 2022 03:00 AM Eastern Daylight Time

First-of-Its-Kind National Canine Cancer Registry Offers Ray of Hope to Dog Lovers

YourUpdateTV

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop a tumor, and almost 50% of dogs over age 10 will develop cancer. Recently, Dr. Susan Ettinger, “Dr Sue Cancer Vet”, Veterinary Cancer Specialist and Take C.H.A.R.G.E. Scientific Advisory Board Member, and Lisa Conte, Jaguar Health Founder & CEO, conducted a satellite media tour to talk about the first-of-its-kind national canine cancer registry that offers a ray of hope to dog-lovers everywhere. A video accompanying this announcement is available at: https://youtu.be/UaYbeRw7JGY Designed to be interactive and with open access to academia, the Jaguar Health Canine Cancer: Take C.H.A.R.G.E. ( C anine H ealth A nd R e G istry E xchange), co-sponsored by Jaguar Animal Health, TogoRun, and Ivee, is a first-of-its-kind national Canine Cancer Registry and Canine Cancer Care Index that provides the veterinary community and canine pet owners with important incidence and prevalence data to help guide canine cancer diagnosis and treatment decisions, at no cost. The Registry began with a retrospective review of more than 35,000 anonymous canine patient records uploaded into a secure customized database and more than 830 confirmed cancer diagnoses and is interactive. Protecting dogs from cancer begins with knowing its impact by breed, type, age, gender, and location Powered by animal health software company Ivee (Intelligent Veterinary Enhanced Experience), only information from canine patients that have been diagnosed with cancer is accessed and data is continuously protected. All research and academia related activities are de-identified and anonymized, following all General Data Protection Regulation (GDPR) guidelines, to ensure 100% participant and veterinary information protection. Currently there is no published state-by-state registry in the U.S. documenting canine cancer, while there are multiple regional European registries that exist and serve to inform both the veterinary and human oncology communities. The Registry also includes the first nationwide Gallup survey of pet owners addressing their experience with canine cancer. Canine Cancer Impact on Humans - Dealing with canine cancer has a major impact on dog owners’ well-being, including depression, anxiety, lack of sleep, and missing work or other obligations; for example, 63 percent of respondents reported feeling a lot of stress and 58 percent reported feeling down and depressed a lot during their dog's cancer. And, more than 8 in 10 dog owners favor the creation of a canine cancer registry to better understand the disease and advance treatments The survey found that the incidence – the percent of U.S. dogs newly diagnosed with cancer in 2021 – was approximately five times incidence of newly diagnosed cancer in humans that year, which is startling since researchers have assumed that canine cancer rates mirror human cancer rates. A complementary Index was established based on pet owner responses to this multi-year nationwide Gallup survey assessing pet owner experience with their dog’s cancer diagnosis and treatment. Together the Registry and Index provides the veterinary community with important information to guide canine cancer diagnosis and treatment decisions and support dog owners by improving canine cancer care. The Gallup survey closed on March 30, 2022, with over 3,800 respondents, including over 600 responses from dog owners with canine cancer experience. Canine cancer patient records uploaded to the Registry are updated regularly thanks to ongoing input from participating veterinarians and owners of dogs who have been diagnosed with cancer. If your dog passed away from cancer, you can contribute to building hope for all dog lovers by uploading your canine pet’s medical records as well. How to get involved as a veterinarian: · If you are a veterinarian and interested in having your clinic/practice opt into the Take C.H.A.R.G.E. Registry, please visit TakeChargeRegistry.com to fill out the Veterinarian Practice Registration form. · All research and academia related activities will be de-identified and anonymized to ensure 100% participant and veterinary information protection. · Once you opt in, the Take C.H.A.R.G.E. Registry will have access to all of your current and newly diagnosed canine patients with cancer. These files will be automatically uploaded into the Take C.H.A.R.G.E. Registry in real time, so no further action is needed once you opt in. How to get involved as a dog owner: · If you are a pet owner and have a PDF of your dog's medical records, simply upload them into the Registry by visiting TakeChargeRegistry.com. · If you do not have your dog's medical records, tell your veterinarian about the Registry at your next visit and encourage them to join! · Follow us on our social channels and reshare with your friends! @Take C.H.A.R.G.E. @takechargereg @takechargeregistry --------------------------- About Susan Ettinger Dr. Sue Ettinger is a practicing veterinary cancer specialist, international speaker, book author, and vlogger (video blogger). She is one of approximately 450 board-certified specialists in medical oncology in North America and currently practices at Veterinary Referral and Emergency Center in Norwalk, Connecticut. She is co-founder and Chief Medical Officer of Fidu, a teleconsulting company to bring together general practice veterinarians and boarded veterinary specialists. She received her veterinary training at Cornell University College of Veterinary Medicine. She completed her residency in medical oncology at the Animal Medical Center in NYC in 2003. She was voted the 2019 Western Veterinary Conference (WVC) Small Animal Continuing Educator of the Year and has recently received awards for Exceptional Doctor Performance and the Public Relations Achievement. Also known as Dr Sue Cancer Vet®, Dr. Sue is the co-author of the Second Edition of The Dog Cancer Survival Guide, which is a best-selling book in small animal health for the last several years. She is a frequent contributor to many veterinary publications, including Today’s Veterinary Practice, Today’s Veterinary Business, Clinician’s Brief, Veterinary Team Brief, & DVM360. She also has co-hosted the podcast The Pet Cancer Vet and is a frequent guest on many veterinary podcasts. There are many myths and misconceptions about cancer in dogs and cats. Most cancers are treatable, and there are a variety of treatment options. Dr Sue’s focus is to provide comprehensive and compassionate care. She strives to minimize side effects – from the cancer itself and treatment – to help her patients lead active, normal lives even while undergoing treatment. Her motto is live longer, live well. Dr. Sue is most passionate about raising cancer awareness, and she has developed “ See Something, Do Something, Why Wait? Aspirate.® ” to promote early cancer detection and diagnosis. This cancer awareness initiative for skin and superficial tumors in dogs and cats provides a set of guidelines for pet owners and veterinarians to help identify the best management for skin and subcutaneous (under the skin) masses in dogs and cats. Masses must be sampled and evaluated under a microscope to determine what they are. The sooner we determine whether a mass is cancerous and should be removed, the better for our pets. Most skin and subcutaneous tumors can be cured with surgery alone if diagnosed early when masses are small. Early detection saves lives. Lisa Conte, Jaguar Health Founder & CEO Lisa Conte is the founder, president and chief executive officer, and a member of the board of directors of Jaguar Health, a commercial-stage pharmaceuticals company committed to discovering, developing and commercializing plant-based prescription medicines for urgent global health needs. Mytesi®, the company’s FDA-approved drug product, is a first-in-class, plant-based anti-secretory agent and the first oral drug approved under FDA Botanical Guidance. In 1989, Ms. Conte also founded Shaman Pharmaceuticals, Inc. and has pioneered plant-based prescription medicine investigation and development for more than 30 years, including a recent Entheogen Therapeutics Initiative looking at psychoactive plants for novel cures for mental health disorders; and Napo Therapeutics, S.p.A., a company established in Italy with a focus on the treatment of rare diseases from plant-based prescription medicines under license from Jaguar Health. Ms. Conte is currently a member of the board of directors of the Healing Forest Conservatory and Napo Therapeutics, and serves on the Editorial Advisory Board of Life Science Leader magazine. She holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth College, and is also the parent of two Jack Russell Terriers and a Belgium Warmblood. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 21, 2022 05:00 PM Eastern Daylight Time

Video

NextFerm Technologies Announces First Commercial Production of ProteVin™, Its Vegan Protein

NextFerm Technologies Ltd.

This marks the achievement of first out of five strategic milestones set by the company for 2022 The Company expects to supply first orders of ProteVin™ in the coming weeks; Company is currently in dialogues with food and dietary supplement global companies for the integration of ProteVin™ in their alternative product lines NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, yeast-based, non-GMO protein alternative and other innovative yeast-based nutrients, today announced the end of commissioning period of the commercial facility in Canada and first commercial production of ProteVin™, Its Vegan Protein. The operation of first commercial facility following commissioning and successful production of first batches mark the achievement of the first milestone out of five milestones set by the company for 2022. The Company continues to progress towards achieving the rest of its objectives for 2022, including delivery of initial orders received, increasing market demand for ProteVin™, receipt of additional purchase orders and expanding penetration into the global food market. In parallel, increasing commercial production capacity to an industrial scale of hundreds of tons per year in 2023. Boaz Noy, Chief Executive Officer of NextFerm, said: "Initiating commercial production of Protevin™, marks a significant milestone for the company moving forward from R&D phase to commercial phase. Achieving this milestone allows us to progress towards achieving the additional milestones we set for 2022. In the coming weeks, we expect to supply first orders of ProteVin™ for customers in the field of sports nutrition formulas." "The alternative protein market is the main growth engine of the global food industry, and we expect high demands for Protevin™, as a proprietary vegan protein source for a variety of alternative food products, with a rich amino acid composition similar to animal-based protein, highest digestibility factor (PDCAST=1) and neutral flavor." About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE: NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein alternative with nutritional value that is similar to animal-derived protein (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor, with no aftertastes that are typical of plant-based protein. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. NextFerm has just commercialized the product as reported. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

June 20, 2022 10:05 AM Eastern Daylight Time

UK MEDTECH COMPANY TO HELP PROTECT US HEALTHCARE WORKERS AND US CITIZENS FROM 1 MILLON NEEDLESTICK INJURIES EACH YEAR

NeedleSmart

SAFETY INITIATIVE AND COMPLIANCE WILL SAVE AMERICAN HEALTHCARE INDUSTRY $1 BILLION British smart MedTech company NeedleSmart, which is pioneering disruptive technologies in the global healthcare sector, is expanding into the US healthcare market to protect American healthcare workers and patients from the rising tide of needlestick injuries (NSI). In the US alone, more than 1 Million NSI are reported each year, affecting frontline nurses, healthcare workers and patients. However, it is estimated that the more accurate figure may be five times that number, due to a culture of underreporting. Initially NeedleSmart will focus their efforts on helping the US healthcare system reduce Needlestick injuries (NSI). Pre Covid-19, NSI cost the US healthcare industry more than $1Bn each year. A cost built on treatments (both physical and mental), absenteeism, agency staff and in many cases law suits. Approximately 5.6 million healthcare workers in the US are at risk of occupational exposure to bloodborne pathogens via NSI or other sharps-related injuries, according to the Occupational Safety and Health Administration every year. Needlestick injuries are caused when a hypodermic needle accidentally punctures the skin. These injuries – which can happen at any time, however the NSI which carry the most significant risks are those that happen after exposure to the patient. The Centre for Disease Control and Prevention (CDC) estimates that at least 385,000 NSI occur each year to hospital-based healthcare workers, amounting to more than 1,000 NSI per day amongst hospital healthcare staff. Many more of those NSI also occur through emergency services, homecare and nursing homes. The CDC has also targeted the elimination of NSI as an agency priority, with both federal and state laws increasing enforcement of NSI injury prevention. Over 41% of NSI occur during use, with 41% occurring after use and before disposal, 15% occurring during and after disposal and 4% in other settings. NeedleSmart is working closely with lawmakers and Government agencies in the US to inform, advance and extend legislation that will protect healthcare workers and frontline staff. US based NeedleSmart Chief Operating Officer Michael Barron said: “Needlestick injuries were already a serious global problem pre Covid-19, with more than 3 million reported cases each year and rising. The introduction of a global vaccination program has added significantly to this with pandemic with NSI statistics yet to be made publicly available. The global supply and use of needles is at an all-time record, which means the risk of becoming injured by a NSI has also greatly increased. If we factor into this equation that hospitals, emergency services and healthcare staff are under even more pressure, facing longer shifts and suffering from burnout and chronic fatigue, this creates the perfect storm for an unprecedented increase and risk of NSI to US healthcare and frontline emergency services staff. While the reported figure of NSI in the US is 1 Million, it is believed that the actual figure could be considerably more due to a culture of under reporting NSI. With NeedleSmart, we can not only reduce and prevent NSI to key frontline healthcare staff, EMS personnel and patients, but we can increase staff efficiencies as we link our bespoke software solutions directly to the NeedleSmart Pro hardware and eliminate significant amounts of pre and post procedure administration and in-efficiency. Our audit and compliance software runs alongside the safe destruction technology to create a singular end to end workflow. NeedleSmart will significantly reduce post procedural PPNSI, directly targeting and reducing the $1Bn per year associated costs.” NeedleSmart, which has offices in Liverpool, England and Philadelphia USA, is already at the forefront of pioneering disruptive technologies with the British National Health Service (NHS) to prevent NSI to NHS healthcare workers and clinicians. It is also developing carbon reduction strategies in clinical waste disposal, as well as digitising vaccination programmes NeedleSmart has achieved FDA approval as a Class II medical device, making it the first UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD)). The NeedleSmart Pro device destroys a contaminated hypodermic needle in a sealed chamber in just 6 seconds, minimizing post-procedural NSI. The device heats the needle to 2372 degrees Fahrenheit, killing potentially harmful pathogens, viruses and bacteria adhering to the needle. Within seconds, the needle is compressed into a tiny ball and released from the NeedleSmart device as a safe sphere of metal at the tip of the syringe. The product can be seen here https://youtu.be/C968RkWtSi8 Aligned with this Needle Smart have set the ambitious goal of re-purposing this waste away from plastic sharps containers to a 96% recycled cardboard clinical waste container in the near future. NeedleSmart has developed a ground-breaking set of disruptive technologies in digital data and AI for medical and clinical records, healthcare worker safety and carbon reduction programs in clinical waste. To learn more about how the Needle Smart Pro works with the DVS system can be seen here https://www.youtube.com/watch?v=nIAzsMwyBDc NeedleSmart’s disruptive smart MedTech technologies are focussed on: Safety: The reduction and hopeful elimination of harmful post procedural NSI to US healthcare workers and patients Sustainability: Reducing the associated carbon footprint by up to 95% Efficiency: The digitalization of vaccination programs, medical treatments, clinical workflows and associated records. Cliff Kirby, NeedleSmart’s Global CEO, added “Not only is this the world’s first safe needle destruction technology that also has FDA 510 (k) approval as a Class II medical device (Sharps Needle Destruction Device (NDD)), but it is the only Smart MedTech to have a unique compliance and audit software each time a needle is used. “When used as part of a vaccination program, our system offers 30-50% increased efficiencies, providing unique compliance with a digital audit trail from the point of when the needle is unwrapped from its sterile packaging. This provides a full audit trail and compliance including, vaccination batch and manufacturer, the healthcare professional administering the vaccination, date, time and patient details – right through to the safe destruction of the needle. This firmly puts healthcare and EMS worker safety at the forefront.” ENDS For more information on Needle Smart, visit www.needlesmart.com www.digitalvaccination.com The Needle Smart process explainer https://youtu.be/C968RkWtSi8 The Needle Smart DVS explainer https://www.youtube.com/watch?v=nIAzsMwyBDc ABOUT NEEDLESMART NeedleSmart is a market-leading, British-patented needle destruction technology engineered in the UK, with offices in Knowsley and Pittsburgh, Pennsylvania. Its award-winning NeedleSmart Pro needle destruction device has achieved FDA approval as a Class II medical device, being the first UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD)). As well as contributing to the reduction of needlestick injuries and their consequential costs, the NeedleSmart process has the potential to reduce the cost and increase efficiency of used needle disposal. NeedleSmart’s innovative technology also offers the opportunity to move hypodermic needles, syringes and consumables associated with the injection/vaccination process, away from conventional sharps bins to a solution that allows recycling to become a possibility. NeedleSmart technology compresses the needle, significantly reducing the needle footprint leading to a minimum of 50% increase in needle count per sharps bin. After the unexpected Covid-19 pandemic and the mass vaccination program that followed, NeedleSmart's Digital Vaccination System (DVS) was created to support mass vaccination program, digitalizing the vaccination process, with every detail being automatically recorded in the cloud. DVS delivers a single solution that can coordinate every individual vaccination initiative into a single, coherent vaccination program. ABOUT MICHAEL BARRON CHIEF OPERATING OFFICER NEEDLESMART US Michael Barron has spent the last 30 years helping to build, scale, and lead high growth companies. As both an investor and executive, he has helped take several firms from inception to over $1Bn in assets. Michael has been featured in The Wall Street Journal and Investor’s Business Daily. He has been a regular guest on Bloomberg and CNBC. He is a board member at The Foreign Policy Research Institute and The Satell Institute. He a graduate of Villanova University. For more information https://www.linkedin.com/in/michaelbarron100/ MEDIA NOTICE NeedleSmart assets and images can be downloaded here https://we.tl/t-NQfuq4O9tr Contact Details NeedleSmart Gerard Franklin +44 7791 039636 gerard@i5media.co.uk Company Website https://www.needlesmart.com/

June 20, 2022 12:30 AM Eastern Daylight Time

Modern Weight Loss: What is Personalized Weight Care and Why You Should Try It

YourUpdateTV

According to the CDC, overweight and obesity are risk factors for many serious diseases and health conditions, including heart disease, stroke, type 2 diabetes, and some cancers, all of which are among the leading causes of preventable death. Recently Dr. Rekha Kumar from Found conducted a satellite media tour to talk about personalized weight loss and its benefits. A video accompanying this announcement is available at: https://youtu.be/ZEx5tcYjrlQ It is time we push back against harmful and outdated weight loss culture and start thinking about our overall health and weight care. A poll of 2,000 adults conducted by weight care platform, Found, revealed that 91% have tried at least one strategy for weight loss, with half revealing that they’ve tried 11 different methods of weight loss. According to that same poll: ● 25% of people even confessed to doing up to 16 diets in their lifetime! ● But only 15% described their weight loss experience as “rewarding” ● Respondents felt that losing weight required more sacrifice than having kids ( 33% )! ● 9 in 10 Americans have tried at least one weight loss strategy ● 33% wished they had access to prescription weight loss medications ● Almost four in five (79%) want to be healthier, not skinnier. Found is an evidence-based weight care solution that combines the best of modern medicine with personalized coaching and community. Centered around clinical care and lasting behavior change, Found provides its members with a comprehensive weight loss program that delivers long term, sustainable results. Found designs personalized treatments around every factor that makes people unique — from biology, medical history, mental health, existent lifestyle, goals, and more. Found’s members are supported by the best of consumer technology, and a team that includes doctors to prescribe safe medication, and coaches to guide them on nutrition, movement, sleep, and emotional health. They call this weight care. When diet and exercise don’t lead to effective weight loss, sometimes it’s our biology that’s holding us back. Much of how your body loses, gains, and maintains weight is predetermined by your biology. This means no amount of working out, eating healthy, or sheer willpower can sustain weight loss if your biology’s not set up for it. Medication can, which is why Found offers more medication options than any other program. Online weight loss means Found took the doctor's office out of the equation. The telehealth platform provides one-on-one medical, nutritional, and movement guidance from their experts, through an app that can be accessed anywhere and at any time. Found’s proprietary weight care platform is available via the App Store, Google Play, as well as on joinfound.com Rekha Kumar bio: Dr. Rekha Kumar is recognized as an international leader in the field of Obesity Medicine. She is Chief Medical Officer at weight care platform Found, as well as a practicing endocrinologist at an academic medical center in New York City. She also served as the former medical director of the American Board of Obesity Medicine. Dr. Kumar has lectured internationally on the topic of the medical assessment and treatment of obesity. She has published several papers and textbook chapters in her field and serves as an Associate Editor of the journal Obesity. She is frequently quoted in the media on topics ranging from the diabetes epidemic in the United States to discussing fad diets, exercise trends, and the complications of Covid-19 in patients with obesity. Dr. Kumar’s areas of expertise include the clinical assessment of patients obesity and metabolic syndrome, the effect of obesity on reproductive health and fertility, as well as thyroid disease. Dr. Kumar completed her undergraduate studies at Duke University then received her master’s degree in Physiology from Georgetown University. She continued on to receive her M.D. from New York Medical College and completed her residency training in Internal Medicine at the New York Presbyterian Hospital/Weill-Cornell Medical College. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the Weill-Cornell Medical College/New York Presbyterian Hospital and the Memorial Sloan Kettering Cancer Center. Dr. Kumar has traveled abroad to India, China, and Tanzania to understand the scope of metabolic disease globally. She serves on the board of advisors of the Duke Global Health Institute. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 17, 2022 10:00 AM Eastern Daylight Time

Video

All Things Bugs Achieves World First with US Patent for the use of Insects in Sustainable Food Production

All Things Bugs LLC

All Things Bugs LLC, the world’s leading innovator in the insect industry, today announced that it has received a US patent for its unique production method as it continues to develop pioneering products and research in the use of insects as sustainable food ingredients. US patent No. 11,337,451, issued on May 24, is the first US patent specifically focussed on insects as a food source, and it confirms All Things Bugs and its Founder and President Dr Aaron T Dossey as leaders in their field. The firm also has similar issued patents in Canada and Mexico. All Things Bugs is the world’s first insect-based food wholesaler, and, for the last decade, the company has developed products, services and research to promote insects as a viable alternative to traditional protein sources such as meat and dairy. All Things Bugs has focussed its efforts in four key areas: 1) Food product development 2) Insect processing and ingredients 3) Cutting-edge insect farming automation 4) Insect genomics and genetic engineering The patent provides recognition of the company’s spray-drying technology, and opens up new opportunities for the use of insects in global food production. All Things Bugs’ patented breakthrough involves the development of a new wet-grinding and drying technique that ensures edible insects can be ground into a fine powder. It is a process that works equally well with all insects including superworms, crickets, mealworms, grasshoppers, locusts, katydids, caterpillars or flies - emphasizing its versatility, and making it cost-effective to produce. Crucially, it is an environmentally-friendly and sustainable way to increase protein content across a whole range of foods. The end product is a super fine, light-colored powder with a neutral aroma and flavor, which can be blended with other ingredients to make numerous food and beverage products, such as pasta, baked goods, shakes, smoothies, meat alternatives, puffed extruded snacks, bars, cereals, tortillas, pet food / treats and many others. The growing need for a sustainable source of protein. Global food production has long relied on meat and dairy products as its main source of protein. This has had a devastating impact on the environment, with costly resources required to sustain it. Huge amounts of land are cleared every year for farming and agriculture, with water and feed production for cows, pigs, chickens, and even most plant-based proteins generating massive land and water use as well as vast energy consumption on a global scale. By comparison, insects make up the largest most diverse group of organisms on Earth. They are nature’s most sustainable protein source, yet very little has been done to utilize insects for people and for our planet. All Things Bugs takes a holistic view of the benefits insects can bring to humankind. As well as food production, the company is using genetic engineering technologies such as CRISPR to develop insects as a vehicle to manufacture non-food bioproducts for livestock and wild animal vaccines, antibiotics, biomaterials, enzymes and other applications. Its valuable work continues to benefit researchers, entrepreneurs, farmers, policymakers, and anyone interested in sustainable food production and the industrial use of insects. “This patent represents a historic opportunity for a shift in mindset towards an overall healthier planet,” said Dr Aaron T Dossey, Founder and President of All Things Bugs. “It proves the potential for turning insects into high quality ingredients efficiently and cost effectively. But, more than that, it is an ethical and sustainable solution to the ongoing challenge of scaling up food production without damaging life on earth in the process.” Dr Dossey published the first text book on the subject, Insects as Sustainable Food Ingredients, and is a leading authority in the field, providing valuable guidance on how to develop the insect-based agriculture, food, and biomaterial industries. For further information, contact info@allthingsbugs.com or visit https://allthingsbugs.com/ About All Things Bugs LLC All Things Bugs is the world’s leading innovator in the insect industry. Insects make up the largest most diverse group of organisms on Earth. They are the most sustainable protein source on the planet, beating out other animal and even plant protein sources. They also require far fewer resources such as land, water and feed to produce than animals and most plants, but very little has been done to utilize insects for the benefit of people and our planet. All Things Bugs develops sustainable insect-based solutions, technologies, and products for agriculture, food, and medicine. Contact Details All Things Bugs LLC Dr. Aaron T. Dossey +1 352-281-3643 info@allthingsbugs.com

June 15, 2022 07:00 AM Central Daylight Time

Image

ALDERHEY@NYWHERE™ CREATING A HOSPITAL OF THE FUTURE: “A HOSPITAL WITHOUT WALLS”

AlderHey Innovation / i5 Media

ALDER HEY LAUNCHES GROUND-BREAKING HYBRID DIGITAL HEALTH PLATFORM IN COLLABORATION WITH MICROSOFT AND MINDWAVE. “TODAY’S CHILD, TOMORROW’S HEALTHIER ADULT” Alder Hey Children’s NHS Foundation Trust, one of the world’s leading paediatric healthcare institutions, has today launched a ground-breaking digital platform that is set to revolutionise the way in which patient care is delivered to children and young people. The hybrid health platform AlderHey@nywhere™ is being championed as a “hospital of the future”, where patient and clinical care is delivered in a hybrid world, both physical and virtual, to create a “hospital without walls”. The interactive and immersive digital platform provides a hybrid point of access and patient care for families, children, young people and clinicians to manage, treat, educate and coordinate delivery of their healthcare. Most importantly, it will focus on preventative healthcare and will make patient care more accessible and personalised. https://www.alderheyinnovation.com/alderheyanywhere The technology was developed by Alder Hey Innovation in collaboration with Microsoft and Mindwave as a solution to addressing the finite capacity of hospital and community resources, including both physical space and workforce. This was also paired with an increased demand of accident and emergency admissions, long waiting times for outpatient appointments, and increasing lengths of stay. Alder Hey has a dedicated innovation centre within the hospital and campus, focused on using cutting-edge technologies and innovations to solve the real-world, day-to-day problems faced by children and young people. Alder Hey Innovation believes that by leveraging innovative health tech, digital platforms, data and AI, it can revolutionise the way healthcare is delivered to children and young people. It seeks to break down the traditional barriers for patients when accessing care and personal health information, as well as when receiving therapies and seeking education, creating a future of healthcare that is a “hospital without walls ” with the focus of care being the individual, taking a more personalised and tailored approach. Commenting on the launch of the new digital health platform, Managing Director of Alder Hey Innovation, Claire Liddy, said: “At the moment, healthcare is most often about treating people that are ill. What we want to do is to shift to a more preventative model of care that is individualised and tailored and that empowers children and young people to take ownership of their healthcare and treatment. There are so many different technologies out there now, including wearable technology and devices such as smartwatches that enable you to monitor your health at home. What we needed was a hybrid platform to bring it all together into one place so that families, children and young people could access it, alongside their clinicians at the hospital. “We think the AlderHey@nywhere™ platform will allow us to elevate the level and access to care for children and young people who tell us that they want to be empowered to understand and manage their own healthcare and treatment. It also allows us to move to a more preventative healthcare modelling, making healthcare more individual and personalised.” AlderHey@nywhere™ is a co-development with Microsoft and tech SME Mindwave. The collaboration came together to co-create a hybrid healthcare platform that will create a way of delivering healthcare for children and young people that is far more tailored to the individual, giving them better life chances. Claire Liddy added: “The Innovation Centre at Alder Hey Children’s hospital is a really special and unique place. It’s a dedicated team, all focussed on bringing new technology into healthcare for the benefit of children and young people. We work with a wide range of private sector partners, including tech giants, SMEs, entrepreneurs and universities, to co-invent new technologies and innovations. We have a different mindset and culture of innovation; we are able to move fast and think big, which allows our innovation path to accelerate much faster than the traditional pathways. We are able to fuse healthcare and tech innovation with industry. This fusion brings something special and unique, creating faster-paced technologies.” AlderHey@nywhere™ provides a unique digital platform that is designed with children young people and their families in mind, making it visually aesthetic, engaging and immersive, but also intuitive. At the same time, its dual purpose is engineered for clinicians to monitor, assess and optimise data and clinical workflow in the management and delivery of patient care. Mindwave – which has previously worked with Alder Hey to develop other tech platforms, including AlderPlay and mental health platform CYP As One™ – have been the lead developers on the visual interface of the portal, as well as the interconnectivity and operability of data. Founder and CEO, Kumar Jacob, said: “It has been a privilege to work with Alder Hey Innovation Centre and Microsoft to be responsible for the design and development of the user interface (UI) and user experience (UX) of AlderHey@nywhere™. Our role has been to ensure that the portal is visually appealing and immersive, making sure the experience that young people, children and their families have is engaging, enjoyable, simple-to-use and easy-to-understand. At the same time, we want the complicated data and AI to flow seamlessly to ensure that the data flow of information is interoperable and sent across multiple devices, making the experience seamless, functional and easy for clinicians to use.” AlderHey@nywhere™ enables the interoperability of multiple systems using FHIR, remote devices and resources for management of acute and chronic conditions. Furthermore, it collates a new unique data set for longer-term, AI-augmented decision-making for preventative intervention, personalised care and long-term disease prevention. Umang Patel, Chief Clinical Information Officer at Microsoft, also offers a unique perspective thanks to his dual role at Microsoft and as a paediatrician working in the NHS at Frimley Park Hospital. "It's been a real privilege to work with Alder Hey to develop the AlderHey@nywhere™ platform," he says. "Microsoft always loves projects that gets its staff excited - to be given the opportunity to help children and young people - was one such project. Hopefully we have been able to bring some new insights, skills and innovations that will help Alder Hey not only solve problems locally but scale beyond the Liverpool region. What they have done at Alder Hey is great for many reasons, but two stand out: first, the Alder Hey team has managed to keep it simple. If you ask 100 doctors what they want in an ideal system, they will tell you a million important things. The team has managed to scale that back, kept it usable, and brought the most important things to the front. Second, is the momentum they have generated- it's trailblazing innovation at its best.” AlderHey@nywhere™ was based around a model of prevention and intervention. The digital health platform allows for: A true hybrid of both physical and virtual patient care Remote real-time monitoring of patient care for intervention Creating a platform of care that is tailored and self-managed Digital Bio-markers and IoMT for preventive real time augmented clinical decision making Children and young people want to be empowered to engaged interactively with gamification to understand and manage their care To download our images for AlderHey @nywhere image assets available here https://we.tl/t-IYVZFHiWwj ABOUT US ABOUT ALDER HEY INNOVATION CENTRE – Todays Child, Tomorrows Healthier Adult Alder Hey Innovation is the largest, dedicated, purpose built, hospital led innovation centre in the UK. Alder Hey Children’s NHS Trust has a proud history of innovation spanning over a hundred years. Today we continue that legacy pioneering the use of cutting-edge technology and innovating to save lives and improve the life chances of today’s child. Our ambition is to be the world leader in advancing child health with innovation, utilising our unique hospital-based innovation centre, disrupting, discovering and disseminating to have real impact. Our mission is to solve the real-world healthcare problems children and young people face today, creating fair access to care and enabling a healthier future for all. Our unique strengths lie in our experience to innovate and disrupt, with a strong track record of rapid problem solving, creating an end-to-end pipeline and process from problem identification and solutions through to commercial income. Our strategy is fueled by a bespoke open innovation system, to rapidly identify real-world problems and bring the right partners together to solve those with innovative and disruptive technology. Our co creation approach involves scouting and partnering with local and international industry and academia, bringing the most innovative technology and solutions to Alder Hey, where we strive for excellence and breakthroughs in healthcare. www.alderheyinnovation.com ABOUT ALDER HEY Alder Hey Children’s NHS Foundation Trust provides care for over 330,000 children and young people every year. Alder Hey delivers clinical excellence for all children, for routine illnesses as well as very complex and rare conditions. One of four stand-alone children’s hospitals in the UK, it is a national centre for neuro and craniofacial surgery, a regional centre for burns injuries and a Centre of Excellence for children with cancer, heart, spinal and brain disease. Alder Hey as an NIHR funded Clinical Research Facility (CRF) that specialises in the design, and delivery, of early phase drug trials in children with a wide range of conditions. The Trust is one of only four epilepsy surgical centres in the UK and one of only two accredited major trauma centres in the North West. Alder Hey is also a respiratory Extracorporeal Membrane Oxygenation (ECMO) surge centre and is the referral centre for the treatment of congenital heart defects in North West England, North Wales and Isle of Man. It became the first UK Centre of Excellence for Childhood Lupus in 2010. Alder Hey is the first accredited Investing in Children hospital in the UK. It has a dedicated patient experience programme which includes the award-winning Alder Hey Arts involving music therapy, dance programmes, storytelling and animation projects. It is also one of a few hospitals to have a Children and Young Person’s Forum. Alder Hey opened a new hospital ‘Alder Hey in the Park’ in 2015. Europe’s first hospital in a park, the new facility provides a purpose-built, unique and world class healing environment for children and young people. Alder Hey is supported by The Alder Hey Children’s Charity which aims to raise vital funds for lifesaving equipment, research projects and patient experience initiatives. For more information visit www.alderhey.nhs.uk and www.alderheycharity.org ABOUT MINDWAVE Mindwave (Mindwave Ventures Limited) designs and develops digital applications for healthcare. Mindwave works with NHS organisations, charities and universities to help them develop innovative digital products to deliver healthcare and carry out health research. Mindwave's patient portal is currently deployed in over eight organisations. The company has grown to around 95 staff based in the UK and Pondicherry (South India). Mindwave's designers based in the UK are steeped in user centred design. Design and development follows Government Digital Service (GDS) guidelines and Agile principles. Born out of the NIHR Maudsley Biomedical Research Centre (BRC), Mindwave was founded in 2014; the brain-child of Kumar Jacob MBE, who trained as an accountant and then operated in different guises across a broad range of sectors, including charity, education, health and technology. Having worked with creative teams that brought out hugely popular video games such as Burnout, Singstar, WipeOut at Criterion and Sony, whilst also serving as a non-exec director at SLaM and as the chair at the Maudsley Charity, Kumar could see a disparity between the way that the public sector and the technology sector were solving problems. Enter Mindwave. Over the years, the team has grown from a handful of designers to a full-service provider, supplying expert health design and technology consultancy alongside end-to-end digital service development. To date, Mindwave has worked with a wide range of health focused organisations, including multiple NHS trusts and ICS regions, health focused charities, and a large number of clinical academic teams. Mindwave also works with and supports a number of health-tech startups, providing consultancy, design, development and project management to support peers to successfully enter the market. Mindwave is known for going above and beyond, and for the team’s eagerness to help, converse and collaborate. www.mindwaveventures.com Contact Details Alder Hey Innovation /i5 Media Gerard Franklin gerard@i5media.co.uk

June 10, 2022 02:15 AM Eastern Daylight Time

QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS

Quidel Corporation

With Lyme disease season in full-swing across the United States and as the public continues spending increasing time outdoors during the COVID-19 pandemic, Quidel’s recently formed Lyme Task Force Team—the only one of its kind—today announced a multitiered collaboration with Global Lyme Alliance to dramatically heighten public awareness to a health condition afflicting nearly half a million Americans each year. Quidel is the nation’s leading developer of the only rapid point-of-care diagnostic Lyme disease test. In recent years the company launched the critically acclaimed and award-winning LymeDiseaseAnswers.com website and Lyme Quick Takes online video series. “The Global Lyme Alliance has been a passionate and important partner for Quidel in our fight against Lyme disease,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel. “Over the years they have helped fund the most urgent and promising research in the field while expanding education and awareness programs for the public and physicians. We’re honored to have this collaborative partnership.” As part of its collaboration, Quidel will serve as sponsor for GLA’s Lyme awareness month as well as a series of educational PACE-accredited webinars. These events provide new information on various Lyme topics in an open discussion format, all designed to bring awareness around the Lyme disease epidemic, with rapid ways to diagnose and treat it. In addition, Quidel will be a sponsor for the GLA Global Gala 2022, the organization’s premier fundraising event to be held in October. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’ s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’ s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities, and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

June 09, 2022 06:00 AM Pacific Daylight Time

Sylvester Feddes joins the 2022 Leading Entrepreneurs of the World Conference

1BusinessWorld

Sylvester Feddes, the Country President and Pharma Head of Novartis Colombia, joins the 2022 Leading Entrepreneurs of the World Conference to talk about leading diversity and inclusion in a virtual environment. At Novartis Colombia, Sylvester and his team use innovative science and technology to address some of society's most challenging healthcare issues by discovering and developing breakthrough treatments and finding new ways to deliver them to as many people as possible. The LEW Conference is one of the largest and most comprehensive entrepreneurial events in the world and features business presentations, digital interviews, discussions and roundtables with the world's leading entrepreneurs and business leaders. Register to attend the 2022 LEW Conference to watch the live session of Sylvester's presentation and to connect with him live at the event: https://events.zoom.us/e/view/_LwgIoXQQL2gA_LMBaozZA All news and content distribution in partnership with News Direct. About Novartis Novartis is a leading healthcare company providing solutions to the changing needs of patients. We use science-based innovation to address society's biggest health care challenges. We discover and develop advanced treatments and find new ways to ensure access to as many people as possible. Likewise, we seek to guarantee an effective return for those who invest time, resources and ideas in our company. Our goal is to improve global health. Through our business, we make an important contribution to society: we discover and develop innovative medicines. Novartis works hand in hand with others to help address some of the world's biggest health challenges. Novartis About Leading Entrepreneurs of the World As part of 1BusinessWorld, Leading Entrepreneurs of the World is one of the largest and most comprehensive entrepreneurial platforms and events in the world and features entrepreneurs, founders and business leaders presenting on cutting-edge topics and the latest industry developments. Leading Entrepreneurs of the World About 1BusinessWorld 1BusinessWorld is a global business ecosystem, network and marketplace that provides entrepreneurs, business owners and professionals with the information, tools, resources and connectivity needed to succeed throughout their company’s growth journey, toward a better business world. Our vision is based on the reality that we live, work and do business in one global interconnected business environment, and hence our motto: “One World, One Business World”. Our mission is to encourage and support global communication and collaboration among entrepreneurs, professionals, and businesses. 1BusinessWorld Contact Details 1BusinessWorld Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

June 08, 2022 06:17 PM Eastern Daylight Time